Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2018

View Archived Issues

Filoviruses hide out in sperm production site

Dogs and Duchenne

In rare encephalitis, neurons contribute to their own demise

XPO5 gene polymorphism found to protect from coronary artery disease risk

Kodiak completes enrollment in phase I study of KSI-301 in diabetic macular edema

TACI found to have prognostic value in heart failure

MedImmune patents new fusion proteins for heart failure

I-Mab Biopharma presents anti-CD73 antibodies for cancer

Janssen Pharmaceutica NV synthesizes 5-HT2B receptor antagonists

Immutep advances development of LAG-3 agonist antibody IMP-761

BenevolentAI Bio discloses orexin receptor antagonists

Phase I/IIa study of SYNB-1618 in healthy volunteers establishes dose for patients with PKU

ABX-464 shows promise in phase IIa trial in ulcerative colitis

Synthetic oligosaccharide conjugate vaccine for shigellosis evaluated in phase I trial

MHRA agrees in principle with proposed restart of Redx's phase I/IIa study of RXC-004

An epigenetic signature in non-small cell lung cancer predicts response to anti-PD-1 therapy

Jeil Pharmaceutical presents JP-1366, a potent potassium-competitive acid blocker for treating GERD

Janssen studies JNJ-67953964 in phase IIa for depression

IAVI enrolling healthy volunteers for first-in-human study of eOD-GT8 60mer vaccine, adjuvanted

Daiichi Sankyo studies DS-8201a in phase III trials for advanced HER2-positive breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...